In vitro target validation and in vivo efficacy of p38 MAP kinase inhibition in established chronic collagen-induced arthritis model a pre-clinical study
recombinant from Invitrogen Ltd, Paisley, UK.interleukin IL-1β was Induction and monitoring of CIA
Bovine from type II murine bovine collagen was extracted from mouse sternums (6). Collagen was type II articular collagen cartilage was puri ed and dissolved in 0.05M acetic acid and emul-si ed with an equal volume of Freund’s complete adjuvant (CFA; Difco Becton Dickinson, Cowley, Oxford, UK).
Mice DBA/1 (H-2q) purchased from Harlan used in this study were male UK Limited (Bicester, Oxon, UK). An-imals were housed in individual venti-lated cycle and were fed standard laboratory cages over a 12-hour light/dark chow work Of ce project licence PPL no: 70/5446 was and conducted water ad under libitumthe . Animal Home Pathogenesis and therapy for RAthe operatives of the Animals (Scientif- under ic Procedures) Act 1986.
For induction of acute CIA, 10-12 week old mal mice 100injection received at the a base single of intrader- ed in CFA, containing paraf n oil, and μg bovine type II collagen the emulsi-tail of lyophilised sis Cowley, H37 Ra Mycobacterium (Difco Becton Dickinson, tuberculo-cal oedema and/or erythema involving any signs Oxon, of arthritis UK). were The assessed rst clini-by of the four paws. Onset of disease was observed administration, as previously described from 2 weeks after collagen (3, 7-14).
For the induction of chronic relapsing arthritis, immunised with 10010-12 week old mice type II collagen emulsi ed in CFA by μg of homologous were intradermal injection at the base of the tail. On day 14 after immunisation the mice were boosted with 100mologous μg of ho-clinical signs of arthritis were assessed type II collagen. The rst as for acute CIA, with onset of disease occurring type Freund’s II collagen from 2 boost weeks in after murine mary immunisation), as previously de-adjuvant (4 weeks incomplete after pri-scribed (3, 4, 15).
The treated, mice or inhibitor-treated were randomised into un-(1% DMSO plus 99% methyl cellulose)
GSK678361) and vehicle-treated (GW856553X Following onset of arthritis, mice were treated with GW856553X (0.8mg/kg, 4mg/kg, 10mg/kg daily Fig. 1. GW856553X reduces acute CIA.
or 20mg/kg daily), vehicle alone or left untreated (n=5-8 per group). (over a 10 day period, and data are expressed as mean ± SEM. Statistical analysis was carried out using a) Clinical score was assessed a 2-way ANOVwere sacri ced and paws were sectioned for histological evaluation. Representative sections are shown A versus vehicle-treated mice: ***p<0.001. At the end of the study (day 10), animals as follows: (10mg/kg GW856553X, (b) untreated, (in a blinded fashion for pannus formation, synovitis, and bone and cartilage erosion. Paws were as-gc) 20mg/kg GW856553X. () vehicle-treated, (d) 0.8mg/kg GW856553X, (h) Haematoxylin and eosin sections were scored e) 4mg/kg GW856553X, (f) signed one of three grades: 0=normal; 1=moderate synovitis with some loss of cartilage; 2=extensive synovial histological score (metatarsal, tibia-tarsus, proximal interphalangeal and distal interphalangeal joints). hyperplasia, destruction of cartilage and some bone erosions. Results are mean (± SEM) Statistical analysis was carried out by 1-way ANOVA versus vehicle-treated mice: ***p<0.001.
groups, at the onset of the disease. Treat-ments in ammation; 1: slight oedema or ery-neally (i.p.), from the day of arthritis on-were administered intra-perito-thema; set. Paw swelling was measured with 0-involving the entire paw; 3: pronounced 2: pervading oedema/erythema 10 mm callipers (Kroeplin, Schluchern, oedema Germany). pacitated limb mobility.
and erythema leading to inca-monitored daily and each limb was as-In both models, mice were signed Histological analysis
normal paws and no clinical features of
a clinical score as follows: 0: Hind tem and paws xed were in 4%. removed Fixed

specimens
post-mor-178
p38 inhibition and not MK2 inhibition enhances ...efficacy in in vitro and in vivo inflammatory ... Novel inhibitor of p38 MAP kinase as an anti...
(2013) In Vitro and In Vivo Experimental Models...Efficacy of Antineoplastic Drugs on Urinary Bladder...inhibition are the oldest and most commonly used ...
The potent anti-leukemia efficacy of Icaritin in murine model demonstrated ... Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a...
of 4T1 breast cancer in vitro and in vivo. ...In vivo growth-inhibition of Sarcoma 180 by ...Chemopreventive efficacy of curcumin and piperine ...
namely stimulation of osteoblastic cell proliferation and inhibition of ...In summary, the present study clearly demonstrates the in vivo efficacy of ...
Experimental models of elevated Pgc in vivo ...In vitro mechanical stimulation therefore represents ...of p38 MAP kinase and subsequent inhibition by ...
Target validation Seattle/Chicago: Structure ...(in vitro systems) Biochemical (kinase, protease,...Inhibition Slide 20 deCODE Capabilities: In Vivo ...
In vitro models (enzyme inhibition, receptor ...and in silico) Bottleneck: Target validation, “... www.kubinyi.de MAP Kinase Pathways Kinases www....
[1] Target: p38 MAPK in vitro: In SHR-SPs receiving a salt-fat diet...Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, ...
Efficacy of a Tyrosine... 暂无评价 9页 免费 ...in vitro screening for tyrosine kinase inhibitors ...Also, there is substantial in vivo inhibition of...
热门文档